Company Overview and News
Good day everyone and welcome to the Northern Trust Corporation Third Quarter 2018 Earnings Conference Call. Today’s call is being recorded. At this time, I would like to turn the call over to the Director of Investor Relations, Mark Bette for opening remarks and introductions. Please go ahead.
NTRS NTRSP 3772
KeyCorp (KEY - Free Report) is slated to announce third-quarter 2018 results on Oct 18, before the opening bell. The company is expected to show some improvement in net interest income (NII), driven by higher interest rates and decent loan growth, while the flattening of the yield curve and higher deposit betas will likely to hamper growth to some extent. While the overall loan growth in the third quarter was not impressive, commercial and industrial loans witnessed modest rise.
ABCB NTRS NTRSP PBCT KEY
The Manufacturing - Farm Equipment industry has been witnessing a downtrend over the past five years since peaking in 2013. The decline was mainly due to the impact of low commodity prices and sluggish farm incomes. The industry’s performance has also been impaired by decline in capital spending and fall in demand due to the appreciating dollar. Nevertheless, farm equipment demand has recently picked up mainly driven by the need to replace the aging equipment.
LMT BGG NTRS TWI NTRSP AGCO
Retail sales returned another soft reading in September, weighed down by a drastic drop in spending at bars and restaurants. Spending also dropped at grocery stores and gas stations, leading to fears of a possible economic slowdown. Only a jump in spending at auto dealers staved off an overall decline.
LMT RUSHB NTRS NTRSP ABG AZO AAP RUSHA CRMT
Accurate identification of correctly priced stocks is crucial for successful investing. However, in reality, the correctly priced stocks and overpriced toxic stocks are intermixed in such a way that it is very tough to distinguish between them. Generally, overpriced toxic stocks are vulnerable to external shocks. Moreover, these stocks are burdened with a large amount of debt. The price of these stocks is artificially inflated.
LMT AMC NTRS NTRSP OR AEM
L3 Technologies, Inc. (LLL - Free Report) recently entered a strategic merger agreement with electronics and communication systems provider Harris Corp. (HRS - Free Report) . Unanimously approved by both the companies’ management, the combined company is all set to become a global defense technology leader. Details of the Agreement For fiscal year 2018, the combined company is expected to generate net revenues of approximately $16 billion, Earnings before Interest and Taxes (EBIT) of $2.
LMT NOC NTRS NTRSP HRS UTX COL OA
The 72-year-old firm announced the launch of a separate company, Fidelity Digital Asset Services, on Monday that will handle cryptocurrency custody and trade execution for institutional investors.
WASHINGTON (AP) — This week's dizzying sell-offs in the financial markets have been a rude reminder that the U.S. economy is no longer relying on ultra-low interest rates to fuel growth.
FMCCO FMCCP FMCCM FMCCN NTRSP FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL FMCKI FMCKJ NTRS FMCC FMCCS FMCCT
The market expects Northern Trust (NTRS - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
Global bond markets got stirred up overnight after late afternoon comments by Fed Chairman Jerome Powell, but central bank watchers say investors were making a mountain out of a molehill.
Markets breathed a sigh of relief after Italy’s populist coalition government calmed fears of an explosive clash with the EU by rowing back on its spending plans.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET